Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease

18. februar 2013 oppdatert av: MedImmune LLC

A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease

The primary objective of this study is to identify biomarkers that can be used for evaluation of efficacy in subjects presenting with AECOPD

Studieoversikt

Status

Avsluttet

Detaljert beskrivelse

Identify biomarkers that can be used for evaluation of efficacy in subjects presenting with AECOPD by evaluating longitudinal changes and the interrelationship of blood and sputum biomarkers with physiological endpoints and symptom measures in stable subjects with COPD likely to experience a future AECOPD, and in subjects during severe AECOPD.

Studietype

Observasjonsmessig

Registrering (Faktiske)

61

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Quebec
      • Sainte-Foy, Quebec, Canada, G1V 4G5
        • Research Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Research Site
    • Massachusetts
      • Springfield, Massachusetts, Forente stater, 01199
        • Research Site
    • Missouri
      • St. Louis, Missouri, Forente stater, 63110
        • Research Site
    • New York
      • Buffalo, New York, Forente stater, 14215
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19140
        • Research Site
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02903
        • Research Site
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The subjects in this study will be adult males or females, ≥40 years of age, at increased risk for AECOPD (Cohort 1) or who present with severe AECOPD requiring hospitalization (Cohort 2).

Beskrivelse

Inclusion Criteria:

  • Age ≥ 40 years at the time of screening
  • Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  • Cohort 1 only: A primary diagnosis of clinically stable physician-diagnosed COPD upon entry into the study meeting one of the following criteria:
  • Subjects who have experienced a severe AECOPD requiring inpatient hospitalization in the previous 12 months
  • Subject who had one severe AECOPD requiring ED visits in the past 9 months
  • Subjects who are currently on LTOT.
  • Cohort 1 only: Stable COPD for 4 weeks prior to screening, as defined by no change in ICS therapy and no use of oral corticosteroids or antibiotics for a respiratory tract infection.
  • Cohort 1 only: Forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 0.70 or lower limits of normal (LLN).
  • Cohort 1 only: FEV1 < 60% predicted normal value.
  • Cohort 2 only: A primary diagnosis of physician-diagnosed AECOPD requiring admission to the hospital.
  • Current smoker or ex-smoker with a tobacco history of ≥ 10 pack-years (one pack year = 20 cigarettes smoked per day for 1 year).
  • Ability and willingness to complete the appropriate follow-up period of time as required by the protocol.
  • Able to read and write and use the electronic devices (English or Spanish version).

Exclusion Criteria:

  • Participation (defined as administration of at least one dose of investigational product) in another clinical study, the last follow-up visit of which is within 12 weeks (for a small molecule drug) and (6 months for a large molecule drug) of entry into this study.
  • Any condition that, in the opinion of the investigator would interfere with interpretation of subject safety or study results.
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
  • The presence of another chronic pulmonary or systemic disease, which in the opinion of the investigator or medical monitor might affect the analysis of the data (eg, idiopathic pulmonary fibrosis, sarcoidosis, active cancer or autoimmune disease).
  • History of immunodeficiency.
  • Current alcohol or drug abuse or a history of unsuccessfully treated alcohol or drug abuse within the past year.
  • Cohort 2 only: Diagnosis of an acute disease/condition (eg, congestive heart failure, acute myocardial infarction, pneumonia, or pulmonary embolus) that is the primary reason for the subject's hospitalization.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Cohort 2
Subjects who are recruited on admission to hospital for AECOPD.
Cohort 1
Subjects with COPD who are stable, but at risk of presenting with an AECOPD.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Identify biomarkers for evaluation of efficacy in subjects presenting with AECOPD
Tidsramme: 12 months
Investigate changes in physiological measures, symptoms, and blood, urine and sputum biomarkers in subjects with stable COPD during AECOPD, and as subjects return to clinical stability.
12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hospitalization, treatment and discharge of COPD subjects
Tidsramme: 12 months
Gain an understanding of the reasons subjects with COPD may be hospitalized for their AECOPD and to understand the criteria physicians use for treatment and discharge.
12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Joseph Parker, MD, MedImmune LLC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. februar 2011

Primær fullføring (Faktiske)

1. november 2012

Studiet fullført (Faktiske)

1. januar 2013

Datoer for studieregistrering

Først innsendt

28. desember 2010

Først innsendt som oppfylte QC-kriteriene

28. desember 2010

Først lagt ut (Anslag)

29. desember 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

20. februar 2013

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. februar 2013

Sist bekreftet

1. februar 2013

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • MI-CP221

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere